 |
PolypDx™ is the first and only urine-based test with a high sensitivity for detection of precancerous polyps |
EDMONTON, Alberta -- Metabolomic Technologies Inc. (MTI) announce the launch of a $1.4 million project to evaluate a new colorectal cancer screening strategy using PolypDx™, the first and only urine test for the detection and prevention of colorectal cancer. Through a significant investment from Alberta Innovates, this project will bring together the Alberta Colorectal Cancer Screening Program, Alberta Health Services Public Laboratory Services and the Digestive Health Strategic Clinical Network in coordination with the University of Alberta - School of Public Health- Health Technology Unit, Institute of Health Economics and DynaLIFE Medical Labs.